PLUS1
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 0.35 ▼ -0.01 (-2.78%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Genprex Inc | GNPX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 0.36 | 0.3749 | 0.35 | 0.3749 | 0.36 | 19:59:37 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.35 | 0.376 | 0.026 | 6.91% | 2 | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 581 | 311,580 | $ 0.3585724 | $ 111,724 | 609,984 | 0.231 - 2.49 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:57:28 | 4 | $ 0.37 | USD |
Genprex Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 6.93M | 19.26M | $ -12.37M | -0.89 | - | 18.65M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 3.90% |
Genprex News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/17/2020 | 17:16 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 1/17/2020 | 17:13 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/15/2020 | 06:11 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 1/09/2020 | 08:25 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/06/2020 | 13:21 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/06/2020 | 08:00 | Business Wire | Genprex to Present at Biotech Showcase™ 2020 in San.. |
| 1/02/2020 | 12:46 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GNPX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.36 | 0.46 | 0.3228 | 0.3740968 | 1,061,532 | 0.00 | 0.0% |
| 1 Month | 0.25 | 0.46 | 0.24 | 0.3651047 | 1,071,071 | 0.11 | 44.0% |
| 3 Months | 0.52 | 1.09 | 0.231 | 0.4207508 | 787,969 | -0.16 | -30.77% |
| 6 Months | 1.06 | 1.21 | 0.231 | 0.4507368 | 387,664 | -0.70 | -66.04% |
| 1 Year | 1.51 | 2.49 | 0.231 | 0.5644706 | 217,733 | -1.15 | -76.16% |
| 3 Years | 4.69 | 19.4499 | 0.231 | 3.56 | 180,572 | -4.33 | -92.32% |
| 5 Years | 4.69 | 19.4499 | 0.231 | 3.56 | 180,572 | -4.33 | -92.32% |
Genprex Description
| Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells. |
